SAL0114: a novel deuterated dextromethorphan-bupropion combination with improved antidepressant efficacy and safety profile
BackgroundEsketamine, the first Food and Drug Administration-approved fast-acting antidepressant, has limited use because of its addictive properties. Although the combination of dextromethorphan and bupropion partially addresses the limitations of esketamine, concerns remain regarding neurologic si...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-09-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2024.1464564/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850265208237326336 |
|---|---|
| author | Ying Xiao Xuefeng Hu Wei Xing Jie Yan Ruhuan Wang Xiaoqing Li Jiahuan Li Zhixin Zhang Jingchao Sun Junjun Wu |
| author_facet | Ying Xiao Xuefeng Hu Wei Xing Jie Yan Ruhuan Wang Xiaoqing Li Jiahuan Li Zhixin Zhang Jingchao Sun Junjun Wu |
| author_sort | Ying Xiao |
| collection | DOAJ |
| description | BackgroundEsketamine, the first Food and Drug Administration-approved fast-acting antidepressant, has limited use because of its addictive properties. Although the combination of dextromethorphan and bupropion partially addresses the limitations of esketamine, concerns remain regarding neurologic side effects related to dextromethorphan metabolites, and seizure risks associated with high-dose bupropion. SAL0114, a novel formulation combining deuterated dextromethorphan (in which hydrogen atoms are replaced with deuterium) with bupropion, seeks to enhance dextromethorphan stability through deuteration of its metabolic sites. This approach is expected to increase antidepressant efficacy, reduce metabolite-induced safety issues, and allow for lower bupropion dosages.MethodsRadioligand competition binding assays were used to evaluate the impact of deuterium substitution on the in vitro activity of dextromethorphan and its metabolite, dextrorphan. In vitro hepatic microsomal stability and in vivo mouse pharmacokinetic assays were performed to assess the effects of deuteration on dextromethorphan stability. Two mouse models of behavioral despair were used to determine the antidepressant and synergistic effects of deuterated dextromethorphan and bupropion. Additionally, a reserpine-induced hypothermia rat model and an ammonia-induced cough mouse model were used to assess the in vivo effects from a pathological perspective.ResultsDeuterated dextromethorphan maintained the same in vitro activity as dextromethorphan while exhibiting twice the metabolic stability both in vitro and in vivo. Combination with bupropion further improved its in vivo stability, increasing the exposure by 2.4 times. The combination demonstrated efficacy and synergistic effects in all tested animal models, showing superior efficacy compared with the dextromethorphan-bupropion combination.ConclusionDeuteration improved dextromethorphan metabolic stability without altering its in vitro activity. Bupropion enhanced this stability and synergistically boosted the antidepressant effect by increasing deuterated dextromethorphan exposure in vivo. This enhanced metabolic stability suggests a reduction in dextromethorphan metabolites associated with clinical neurological side effects. Consequently, SAL0114 is hypothesized to offer improved efficacy and safety compared with the non-deuterated combination, potentially allowing for lower bupropion dosages. Further clinical studies are required to confirm these preclinical findings. |
| format | Article |
| id | doaj-art-4f67c2dce63b47188d8cd7e4e6eed45c |
| institution | OA Journals |
| issn | 1663-9812 |
| language | English |
| publishDate | 2024-09-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj-art-4f67c2dce63b47188d8cd7e4e6eed45c2025-08-20T01:54:30ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122024-09-011510.3389/fphar.2024.14645641464564SAL0114: a novel deuterated dextromethorphan-bupropion combination with improved antidepressant efficacy and safety profileYing XiaoXuefeng HuWei XingJie YanRuhuan WangXiaoqing LiJiahuan LiZhixin ZhangJingchao SunJunjun WuBackgroundEsketamine, the first Food and Drug Administration-approved fast-acting antidepressant, has limited use because of its addictive properties. Although the combination of dextromethorphan and bupropion partially addresses the limitations of esketamine, concerns remain regarding neurologic side effects related to dextromethorphan metabolites, and seizure risks associated with high-dose bupropion. SAL0114, a novel formulation combining deuterated dextromethorphan (in which hydrogen atoms are replaced with deuterium) with bupropion, seeks to enhance dextromethorphan stability through deuteration of its metabolic sites. This approach is expected to increase antidepressant efficacy, reduce metabolite-induced safety issues, and allow for lower bupropion dosages.MethodsRadioligand competition binding assays were used to evaluate the impact of deuterium substitution on the in vitro activity of dextromethorphan and its metabolite, dextrorphan. In vitro hepatic microsomal stability and in vivo mouse pharmacokinetic assays were performed to assess the effects of deuteration on dextromethorphan stability. Two mouse models of behavioral despair were used to determine the antidepressant and synergistic effects of deuterated dextromethorphan and bupropion. Additionally, a reserpine-induced hypothermia rat model and an ammonia-induced cough mouse model were used to assess the in vivo effects from a pathological perspective.ResultsDeuterated dextromethorphan maintained the same in vitro activity as dextromethorphan while exhibiting twice the metabolic stability both in vitro and in vivo. Combination with bupropion further improved its in vivo stability, increasing the exposure by 2.4 times. The combination demonstrated efficacy and synergistic effects in all tested animal models, showing superior efficacy compared with the dextromethorphan-bupropion combination.ConclusionDeuteration improved dextromethorphan metabolic stability without altering its in vitro activity. Bupropion enhanced this stability and synergistically boosted the antidepressant effect by increasing deuterated dextromethorphan exposure in vivo. This enhanced metabolic stability suggests a reduction in dextromethorphan metabolites associated with clinical neurological side effects. Consequently, SAL0114 is hypothesized to offer improved efficacy and safety compared with the non-deuterated combination, potentially allowing for lower bupropion dosages. Further clinical studies are required to confirm these preclinical findings.https://www.frontiersin.org/articles/10.3389/fphar.2024.1464564/fulldeuterated dextromethorphanbupropionSAL0114antidepressant efficacymetabolic stabilityC57BL/6J mouse |
| spellingShingle | Ying Xiao Xuefeng Hu Wei Xing Jie Yan Ruhuan Wang Xiaoqing Li Jiahuan Li Zhixin Zhang Jingchao Sun Junjun Wu SAL0114: a novel deuterated dextromethorphan-bupropion combination with improved antidepressant efficacy and safety profile Frontiers in Pharmacology deuterated dextromethorphan bupropion SAL0114 antidepressant efficacy metabolic stability C57BL/6J mouse |
| title | SAL0114: a novel deuterated dextromethorphan-bupropion combination with improved antidepressant efficacy and safety profile |
| title_full | SAL0114: a novel deuterated dextromethorphan-bupropion combination with improved antidepressant efficacy and safety profile |
| title_fullStr | SAL0114: a novel deuterated dextromethorphan-bupropion combination with improved antidepressant efficacy and safety profile |
| title_full_unstemmed | SAL0114: a novel deuterated dextromethorphan-bupropion combination with improved antidepressant efficacy and safety profile |
| title_short | SAL0114: a novel deuterated dextromethorphan-bupropion combination with improved antidepressant efficacy and safety profile |
| title_sort | sal0114 a novel deuterated dextromethorphan bupropion combination with improved antidepressant efficacy and safety profile |
| topic | deuterated dextromethorphan bupropion SAL0114 antidepressant efficacy metabolic stability C57BL/6J mouse |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2024.1464564/full |
| work_keys_str_mv | AT yingxiao sal0114anoveldeuterateddextromethorphanbupropioncombinationwithimprovedantidepressantefficacyandsafetyprofile AT xuefenghu sal0114anoveldeuterateddextromethorphanbupropioncombinationwithimprovedantidepressantefficacyandsafetyprofile AT weixing sal0114anoveldeuterateddextromethorphanbupropioncombinationwithimprovedantidepressantefficacyandsafetyprofile AT jieyan sal0114anoveldeuterateddextromethorphanbupropioncombinationwithimprovedantidepressantefficacyandsafetyprofile AT ruhuanwang sal0114anoveldeuterateddextromethorphanbupropioncombinationwithimprovedantidepressantefficacyandsafetyprofile AT xiaoqingli sal0114anoveldeuterateddextromethorphanbupropioncombinationwithimprovedantidepressantefficacyandsafetyprofile AT jiahuanli sal0114anoveldeuterateddextromethorphanbupropioncombinationwithimprovedantidepressantefficacyandsafetyprofile AT zhixinzhang sal0114anoveldeuterateddextromethorphanbupropioncombinationwithimprovedantidepressantefficacyandsafetyprofile AT jingchaosun sal0114anoveldeuterateddextromethorphanbupropioncombinationwithimprovedantidepressantefficacyandsafetyprofile AT junjunwu sal0114anoveldeuterateddextromethorphanbupropioncombinationwithimprovedantidepressantefficacyandsafetyprofile |